News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Aptiv Solutions Reaches First Milestone in Delivering New Platform for Model-Based Dose-Finding Trials (ADDPLAN® DF)


2/7/2013 9:45:46 AM

RESTON, Va.--(BUSINESS WIRE)--Aptiv Solutions, a biopharmaceutical and medical device development services company, and the leader in adaptive clinical trial design, simulation and execution, announces the completion of a key milestone in the development of a new platform for phase Ib and II adaptive design clinical trials. Both regulatory agencies and the pharmaceutical industry agree that poor understanding of dose response is a major cause of late phase product attrition, and recognize that they need to improve critical decision-making in early stage clinical development so that appropriate doses are progressed to pivotal studies.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES